MARKET

CBLI

CBLI

Cleveland Biolbs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.85
-0.21
-3.39%
Opening 10:20 03/03 EST
OPEN
6.05
PREV CLOSE
6.05
HIGH
6.20
LOW
5.82
VOLUME
25.03K
TURNOVER
--
52 WEEK HIGH
10.97
52 WEEK LOW
1.270
MARKET CAP
89.87M
P/E (TTM)
-28.8357
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER
, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 5d ago
Global Biodefense Market Size 2021, by Type, Application: Covid 19 Impact Outlook and Forecast-2026
Feb 25, 2021 (The Expresswire) -- Global Biodefense Market is valued at USD 5.78 Billion (€ 4.97 Bn) in 2019 and expected to reach USD 8.44 Billion (€ 7.26...
The Express Wire · 6d ago
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Em...
ACCESSWIRE · 6d ago
8-K: CLEVELAND BIOLABS INC
...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/24 04:43
Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock
BUFFALO, NY / ACCESSWIRE / February 23, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has closed its previously announced registered direct offering for the issuance and sale of 2,000,000 shares of its common stock at a purchase pri...
ACCESSWIRE · 02/23 21:30
Prostate Cancer Vaccines Market 2020-2027:Dendreon Corporation, Bavarian Nordic, Advantagene| Ameco Research
pune, India, Mon, 22 Feb 2021 05:28:13 / Comserve Inc. / -- The "Prostate Cancer Vaccines Market Outlook to 2020-2027" report has been added to the Ameco...
Comserve · 02/22 10:29
Choroidal Neovascularization Drug Market Industry Growth,Forecast, Analysis,Manufacturers, Regions, Types and Applications 2020-2027 By Ameco Research
pune, India, Sun, 21 Feb 2021 23:48:52 / Comserve Inc. / -- Choroidal Neovascularization Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/22 04:51
8-K: CLEVELAND BIOLABS INC
(EDGAR Online via COMTEX) -- cbli20210218_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/19 20:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBLI. Analyze the recent business situations of Cleveland Biolbs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 623.22K
% Owned: 4.05%
Shares Outstanding: 15.38M
TypeInstitutionsShares
Increased
0
0
New
6
321.34K
Decreased
3
43.83K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.91%
Pharmaceuticals & Medical Research
-1.94%
Key Executives
Chairman/Independent Director
Lea Verny
President
Langdon Miller
Chief Executive Officer/Chief Financial Officer/Vice President - Finance
Christopher Zosh
Chief Scientific Officer
Andrei Gudkov
Independent Director
Alexander Andryushechkin
Independent Director
Anna Evdokimova
Independent Director
Ivan Fedyunin
Independent Director
Randy Saluck
Independent Director
Daniil Talyanskiy
  • Dividends
  • Splits
  • Insider Activity
No Data
About CBLI
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Webull offers kinds of Cleveland BioLabs, Inc. stock information, including NASDAQ:CBLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBLI stock methods without spending real money on the virtual paper trading platform.